U.S. Food and Drug Administration

Call Directions Website

U.S. Food and Drug Administration The official page of the U.S. Food and Drug Administration. Our posts are all FDA APPROVED! The U.S. Food and Drug Administration or the federal government.

Food and Drug Administration maintains Facebook, Instagram, Threads, X and other social media accounts to share updates about FDA activities and public-health-related information about FDA-regulated products. The FDA has instituted the following policy regarding comments posted to FDA’s social media accounts:

General Comment Guidelines

To maintain respectful interaction on this page, we encourage that all comments:

- Stay focused. All viewpoints are welcome, but comments should be relevant to the specific post under which it appears.
- Be respectful. Respect others’ opinions and share your opinions in a respectful way.
- Tell the truth. Spreading false or misleading information about FDA-regulated products harms the public health.
- No spam. This includes unsolicited commercial messages and a single user’s repeated comments on a topic unrelated to the underlying post. Comment Expectations

Although we hope that you choose to contribute your comments, to protect privacy, please do not disclose personally identifiable information about yourself or other individuals. We welcome your comments and request that you respect the informational resources provided by FDA’s social media accounts. Also, any comments, posts or links that seek to defame, slander or libel any current or former employees (including contractors) of the FDA will be hidden or removed. We will consider your comments when posting new updates, but we may not respond directly to individual inquiries. We are unable to answer questions about your specific health care situation. The FDA does not endorse the comments or opinions provided by visitors to its social media accounts. FDA following users or sharing content does not imply FDA endorsement. We retain the discretion to determine which comments violate our comment policy. We also reserve the right to hide or remove comments and/or disable commenting. The views expressed within posted comments do not necessarily reflect those of the U.S. Comment Moderation

Depending on the platform, comments may be filtered, hidden, and/or removed. We are using these terms to mean the following:

“Filtered” or “filtered and hidden” means that the platform or agency system automatically flagged the comment. It is typically hidden from most users but may still be visible to a limited subset of users.
“Hidden” means that the agency manually flagged the comment to be hidden from most users, but that it may still exist on the platforms in a limited fashion.
“Removed” and “deleted” have the same definition and mean that the agency manually removed the comment from the platform. A record of that removed comment is preserved in accordance with FDA’s Social Media Policy and the Records Retention Schedule. Comments may be automatically filtered and hidden by the social media platform if:

- The comment contains profanity.
- The comment contains an image.
- The comment contains a video.
- The comment contains a link/URL.
- The comment contains keywords from known scam attempts.
- The user does not have a profile picture.
- The user has had their account for one week or less.
- The user does not have any friends or followers.
- The user has had at least three comments reported, deleted, or hidden in the previous 30 days. Comments visible on social media accounts may be hidden or removed by FDA if they:

- Were not hidden despite matching the automated filter criteria as outlined above.
- Appear to be spam, including comments containing commercial endorsements, commercial solicitations, WhatsApp numbers, or a single user’s repeated comments on a topic unrelated to the underlying post.
- Contain discriminatory, racist, offensive, obscene, inflammatory, threatening, or unlawful statements, language, or content.
- Include personally identifiable information for individuals such as email addresses, phone numbers, and mailing addresses.
- Violate the comment policy. Because we want to avoid commercial solicitations and malicious links in our comments, our filters hide comments that contain URLs. To the extent a commenter wishes to reference relevant material available from other sources, please provide a citation or other bibliographic information without including a link. If you think your comment may have been hidden or removed in error, please contact us at [email protected] with details. Records will be kept of all comments that are removed by FDA for the above reasons. We reserve the right to block offenders of this policy.

Each day, generic and biosimilars medications provide essential care for millions of people in the United States and aro...
10/30/2026

Each day, generic and biosimilars medications provide essential care for millions of people in the United States and around the globe.

Next week, FDA leaders will take the stage at to share how the agency supports the development and availability of safe and effective generic and biosimilars medications.

Join us in recognizing the critical role these medicines play in expanding access to affordable, high-quality treatments for millions of Americans. https://www.grxbiosims.org

Important news for women’s health! The FDA just approved updated labeling for three more menopause hormone therapy (MHT)...
10/30/2026

Important news for women’s health! The FDA just approved updated labeling for three more menopause hormone therapy (MHT) products. We are also working to speed up production so that women across the country can get the access to treatments they need.

This is part of our ongoing commitment to women’s health and directly supports an Executive Order signed by President Trump on October 19, 2026, focused on advancing health outcomes of women at every stage of life.

https://www.hhs.gov/press-room/fda-advances-menopause-care-hormone-therapy-labeling-access.html

Your baby’s nutrition matters and so does knowing what’s in their formula. That’s why we’re continuing our work to advan...
10/29/2026

Your baby’s nutrition matters and so does knowing what’s in their formula. That’s why we’re continuing our work to advance the Trump Administration’s commitment to safe, nutritious infant formula for American families.

Today, we proposed updates to some infant formula nutrient requirements: https://www.fda.gov/food/infant-formula-homepage/infant-formula-notice-proposed-rulemaking-infant-formula-nutrient-requirements and released new chemical contaminant testing results through Operation Stork Speed: https://www.fda.gov/food/infant-formula-homepage/fdas-infant-formula-product-testing-results

See what we found and learn about the proposed changes!

10/29/2026
Today, in partnership with the Reagan-Udall Foundation for the FDA, the FDA convened a public meeting as the first step ...
10/28/2026

Today, in partnership with the Reagan-Udall Foundation for the FDA, the FDA convened a public meeting as the first step in the Rare Disease Framework Initiative. This is a joint effort to reimagine the agency's approach to rare disease drug development. This meeting was an opportunity for members of the rare disease community to provide input on the direction and focus of the Framework.

Why now? As FDA Acting Commissioner, Kyle Diamantas, J.D. put it, “We are at the center of a confluence of events for the rare disease community. Our understanding of the science of rare diseases is the best it has ever been, we have made tremendous advances in methods for developing and assessing rare disease therapies, and we have a patient and advocate community that is galvanized and ready to help us focus on the best therapies to help your lives and your families. The urgency of the need has not changed, but now we — the agency, drug developers, researchers, and patients — are ready to meet that need together."

Today's conversation focused on four critical topic areas:
1. Fit-for-purpose review of rare disease therapies based on attainable evidence, particular disease state, and population.
2. FDA consistency and predictability of drug development and review regulatory requirements.
3. FDA engagements with external parties – including patients, disease experts, and researchers – to inform review decision-making.
4. Considerations for chemistry, manufacturing, and controls (CMC) specific to rare disease therapies.

FDA-approved treatments exist for just 5% of rare diseases, and that gap is exactly why this work matters. The Rare Disease Framework Initiative will help inform new guidance, potential regulatory updates, staff training, and possible organizational changes to better serve patients who have been waiting for far too long.

Couldn't attend? You can still make your voice heard. The public docket is open until Dec. 11. We encourage patients, advocates, industry, researchers, and all interested stakeholders to submit written comments and help shape the future of rare disease drug development. https://www.federalregister.gov/documents/2026/10/16/2026-21142/fit-for-purpose-rare-disease-framework-initiative-public-meeting-request-for-information-and

Explore HR Careers at FDA and discover how your HR expertise can help protect and advance public health! Join FDA for a ...
10/28/2026

Explore HR Careers at FDA and discover how your HR expertise can help protect and advance public health! Join FDA for a webinar on Tuesday, November 17, 2026 from 11:00 a.m. – 1:00 p.m. ET

We're actively recruiting for HR roles:
• HR Recruitment & Staffing Specialist | Title 21 Bands A–C (equivalent to GS-11 to GS-13)
• HR Classification Specialist | Title 21 Bands A–C (equivalent to GS-11 to GS-13)

Come meet our leadership, connect with hiring managers, and learn about the hiring process. Don't miss this opportunity to bring your HR career to the agency at the forefront of public health!

Register now to secure your spot: 16d2e86e-2606-44fd-bfba-cc84ecc5320a@7d2fdb41-339c-4257-87f2-a665730b31fc" rel="ugc" target="_blank">https://events.gcc.teams.microsoft.com/event/16d2e86e-2606-44fd-bfba-cc84ecc5320a@7d2fdb41-339c-4257-87f2-a665730b31fc

Women, your heart health matters❤.️   is the leading cause of death for women in the U.S. — but it doesn’t have to be. F...
10/28/2026

Women, your heart health matters❤.️ is the leading cause of death for women in the U.S. — but it doesn’t have to be. FDA Office of Women’s Health has tips to help you take charge of your heart health.
www.fda.gov/womenshearthealth

Address

10903 New Hampshire Avenue
Silver Spring, MD
20993

Alerts

Be the first to know and let us send you an email when U.S. Food and Drug Administration posts news and promotions. Your email address will not be used for any other purpose, and you can unsubscribe at any time.

Shortcuts

Share

Nearby government services